Vaccination against equine influenza: Quid novi?

被引:96
作者
Paillot, R. [1 ]
Hannant, D. [1 ]
Kydd, J. H. [1 ]
Daly, J. M. [1 ]
机构
[1] Ctr Prevent Med, Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England
关键词
influenza; vaccine; horse species;
D O I
10.1016/j.vaccine.2006.02.030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Equine influenza virus is a leading cause of respiratory disease in the horse. Equine influenza vaccines containing inactivated virus were first developed in the 1960s. Despite their intensive use, equine influenza outbreaks still continue to occur and therefore new strategies of vaccination are necessary to improve vaccine efficacy. Numerous methods of vaccination have been evaluated and commercialised in the horse, the most recent being the cold-adapted influenza virus and poxvirus-based vaccines. As a large animal model, the horse is also a useful species in which to evaluate the potential of new generations of influenza vaccine such as live-attenuated influenza virus engineered by reverse genetics. This report details the equine immune responses conferring protection against influenza. It then undertakes a selective review of different strategies of vaccination against equine influenza that have been developed over the last two decades and discusses factors that may influence the efficacy of vaccination. Finally it outlines progress in the development of a novel vaccination strategy against equine influenza using reverse genetics. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4047 / 4061
页数:15
相关论文
共 96 条
[71]   A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM™ vaccines and conventional vaccines [J].
Rimmelzwaan, GF ;
Nieuwkoop, N ;
Brandenburg, A ;
Sutter, G ;
Beyer, WEP ;
Maher, D ;
Bates, J ;
Osterhaus, ADME .
VACCINE, 2000, 19 (9-10) :1180-1187
[72]   IMMUNIZATION WITH A VACCINIA VIRUS RECOMBINANT EXPRESSING HERPES-SIMPLEX VIRUS TYPE-1 GLYCOPROTEIN-D - LONG-TERM PROTECTION AND EFFECT OF REVACCINATION [J].
ROONEY, JF ;
WOHLENBERG, C ;
CREMER, KJ ;
MOSS, B ;
NOTKINS, AL .
JOURNAL OF VIROLOGY, 1988, 62 (05) :1530-1534
[73]   ISCOM™-based vaccines:: The second decade [J].
Sanders, MT ;
Brown, LE ;
Deliyannis, G ;
Pearse, MJ .
IMMUNOLOGY AND CELL BIOLOGY, 2005, 83 (02) :119-128
[74]   Plasmid-only rescue of influenza A virus vaccine candidates [J].
Schickli, JH ;
Flandorfer, A ;
Nakaya, T ;
Martinez-Sobrido, L ;
García-Sastre, A ;
Palese, P .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1416) :1965-1973
[75]  
SINGH G, 1994, ACTA VIROL, V38, P25
[76]  
Slater J, 2000, VET CLIN N AM-EQUINE, V16, P49
[77]   Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination [J].
Soboll, G ;
Horohov, DW ;
Aldridge, BM ;
Olsen, CW ;
McGregor, MW ;
Drape, RJ ;
Macklin, MD ;
Swain, WF ;
Lunn, DP .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2003, 94 (1-2) :47-62
[78]   Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response [J].
Soboll, G ;
Nelson, KM ;
Leuthner, ES ;
Clark, RJ ;
Drape, R ;
Macklin, MD ;
Swain, WF ;
Olsen, CW ;
Lunn, DP .
VACCINE, 2003, 21 (21-22) :3081-+
[79]  
SOVINOVA O, 1958, Acta Virol, V2, P52
[80]  
STUDDERT M.J., 1996, VIRUS INFECT EQUINES, P281